A short review on antibody therapy for COVID-19. (May 2020)

• Record Type: Journal Article
• Authors: Venkat Kumar, G.; Jeyanthi, V.; Ramakrishnan, S.
• Is Part Of: New microbes and new infections. Volume 35(2020)
• Publication Date: 2020-05
• Subjects: Convalescent plasma therapy -- monoclonal antibody therapy -- receptor binding domain -- SARS-CoV-2 -- spike protein; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1016/j.nmni.2020.100682
• Languages: English
• ISSNs: 2052-2975

Abstract

Abstract: The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75, 900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.